with time may include autoimmune and alloimmune processes and an intrahepatic environment that is toxic as a consequence of exposure of islets to high concentrations of immunosuppressive drugs; the relatively low oxygen concentration in the liver may also play a role. 10 Monitoring of graft function 11 is therefore of importance in the follow up care of patients to identify individuals who may require metabolic or immunologic support to prevent further graft loss.
Measures of beta-cell function may be made directly from circulating C-peptide concentrations 12 after stimulation with arginine 13 and glucagon tests 14 or indirectly using surrogate measures, for example using continuous glucose monitoring systems. 15, 16 Recently, it has been demonstrated that a measure of ITx engraftment may be derived from a fasting C-peptide measurement, 11 but islet transplantation programmes across the world have long recognized stimulated C-peptide measurements as an appropriate primary outcome measure. 2, 4, 17, 18 The most used method for stimulating C-peptide response in islet transplant recipients in clinical settings is the mixed meal tolerance test (MMTT) as it is highly reproducible and represents a robust but physiological stimulus for C-peptide secretion with a lower risk of hyperglycemia, because a smaller load of glucose is used, as compared to an OGTT. 19 In the MMTT, a liquid meal is ingested in the fasting state with timed measurements of C-peptide and other metabolites post-prandially. In islet transplantation programmes, the post-prandial C-peptide concentration at 90-minutes is taken to reflect the peak stimulated circulating C-peptide concentration and is interpreted in the context of the glucose concentration at this time point. 20 The purpose of metabolic testing with MMTT after islet transplantation is to assess graft function rather than to define glucose intolerance or recurrence of diabetes. This is in contrast to the use of OGTT to diagnose degrees of glucose intolerance including impaired fasting glucose, impaired glucose tolerance and post-transplant diabetes in other transplant settings, 21 using the same thresholds defined by the WHO (plasma glucose ≥11.1 mmol/L (200 mg/dL) 2 hours after a 75 g oral glucose load) to diagnose diabetes in the general population 22 (See Appendix S1-WHO Classification of Glucose Intolerance). The presence of diabetes nevertheless indicates inadequate insulin secretion (in absolute or relative terms) to maintain euglycaemia. [23] [24] [25] [26] Thus the excursions in glucose and Cpeptide after either a MMTT and OGTT reflect beta-cell capacity.
As OGTTs are not performed routinely and no previous studies have explored the responses to both MMTT and OGTT in islet transplant recipients, we sought to compare the metabolic responses to MMTT and OGTT in a small cohort of insulin-independent islet transplant recipients who had undergone both tests. This also afforded the opportunity to determine the glucose thresholds at 90-minutes following a MMTT that corresponded to the threshold for diagnosis of diabetes after a 75 g-OGTT.
| RE S E ARCH DE S I G N AND ME THODS
In the original Edmonton Protocol, beginning in 1999, MMTTs were performed routinely before and at 3, 6, 12, and 18 months,
and OGTTs performed at 6 and 12 months, post-transplant. 18 Subsequently, OGTTs were performed infrequently as patients disliked exposure to large glucose loads and generally only in insulinindependent subjects. We analyzed data from metabolic studies performed between 1999 and 2003 in subjects who had received their first islet infusion before 2002. The induction and maintenance immunosuppression received by subjects reflects the original Edmonton Protocol (daclizumab at induction and maintenance with sirolimus (8-10 ng/mL) and tacrolimus [4-6 ng/mL]).
| Participants
Data from thirteen insulin-independent islet transplant recipients from Edmonton, with stable graft function, defined as capillary blood glucose readings <10 mmol/L (tested 4 times per day over the previous 1 month), without exogenous insulin therapy or oral hypoglycemic agents with HbA1c <7% (53 mmol/mol) and normal renal function (eGFR>60 mL/min) and who had undergone paired MMTTs and OGTTs are presented.
| Metabolic studies
Three days before all studies, participants were asked to consume 250 g carbohydrates per day and abstain from alcohol or strenuous exercise, after which participants were studied in the Clinical
Research Facility after an overnight fast of 8-10 hours. The MMTT and OGTT tests took place on separate study days. The order of the paired tests were randomised.
Height was recorded to the nearest 0.5 cm, weight to the nearest 0.1 kg (SECA 761 scales) and information regarding medications over the previous 1 week recorded. All participants had a 44-mm, 20-gauge cannula inserted in the left forearm for venous blood sampling. Participants acclimatized for 30 minutes prior to the ingestion of glucose or the mixed meal as previously described. 27 The participant remained seated for the duration of the test.
| Standardized MMTT
Sampling for glucose and C-peptide was performed at baseline and 90-minutes after drinking Ensure HP (6 mL/kg body weight to a maximum of 360 mls consumed within 5 minutes, providing 1.1 Calories/mL; 23% fat, 55% carbohydrate and 22% protein). 
| Data analysis
Measures of insulin resistance were derived from the HOMA-IR 28 and the Matsuda index 29 as measures of hepatic insulin resistance and whole body insulin sensitivity respectively. 30 The insulinogenic index was derived as a surrogate measure of insulin secretion 31, 32 and the disposition index (DI) derived from the product of the Matsuda index and the insulinogenic index 30 ; a DI <1 is evidence of diminished insulin secretion in relation to the insulin sensitivity.
Beta 27 and BETA-2 scores 11 were calculated as composite measures of graft function (See Appendix S1 -Formulae of Scores). TA B L E 1 Personal data of subjects specificity was also derived from the ROC curve analyses. In post hoc analyses, ROC curves of the MMTT data were constructed using a DI <1 and the specificity and sensitivity of the 90-minute MMTT-glycaemic thresholds generated in the primary analysis were derived.
| Statistical analyses
Statistical significance was set at 5%.
| RE SULTS
Seventeen paired OGTTs and MMTTs were performed in 13 participants; 9 participants received one OGTT and one MMTT; four participants received two OGTTs and MMTTs ((mean ± SEM) 6 ± 1 months between each paired study).
The time interval between first transplant and the metabolic test was (mean ± SEM) 15 ± 2 months. The paired MMTTs and OGTTs were performed a median (IQR) of 2 (1-2) days apart.
The personal data of the subjects is shown (Table 1) Basal and stimulated C-peptide concentrations after OGTT and MMTT are presented in Tables 2, 3 and 4. The increment in C-peptide was greater after OGTT vs MMTT (P < .01; Table 4 ). However, the change in C-peptide in relation to the glucose concentrations, did not differ as evidenced by the AUC C-peptide in relation to the glucose concentrations (Table 4) .
When comparing studies with and without OGTT 120 ≥11.1 mmol/L there was no difference in HbA1c, beta or BETA-2 scores between the subgroups (Table 2) (Table 2 ).
In contrast to the OGTT, there were no significant differences in the fasting and 90-minute glucose and C-peptide concentrations or in the 90-minute C-peptide: glucose concentrations; AUCs for glucose and C-peptide between 0-90-minutes; and the C-peptide: Integrated AUCs (0-90-minutes) for glucose and C-peptide were significantly greater following OGTTs vs the MMTTs (P < .001; Table 4 ).
When the analyses were repeated without the second observations in the 4 subjects, all results remained statistically significant. 
| D ISCUSS I ON
This study in insulin-independent islet transplant recipients with stable graft function and normal renal function, examined metabolic The MMTT is a valuable tool used to quantify graft function, rather than to identify glucose intolerance. Nevertheless, postchallenge glucose concentrations were significantly higher after OGTT than post-MMTT which is consistent with the MMTT being a more physiological and less potent stimulus of insulin secretion and therefore a less stringent challenge to graft function. While the post-MMTT glucose levels were not able to reliably discriminate between those with and without OGTT 120 ≥11.1 mmol/L, both OGTT and MMTT were useful stimuli for insulin secretion measured by AUC for insulin and C-peptide. Such physiological testing with a standardized MMTT which contains less than half the amount of carbohydrate compared to a 75 g-OGTT, avoids unnecessary hyperglycemia therefore exposing the islet graft to less metabolic stress, is the preferred option to assess graft function following islet transplantation and is widely adopted by islet transplantation programmes worldwide permitting comparisons between subjects or within subjects over time. 4, 27 Furthermore, such physiological testing has been adopted in new onset diabetes trials including TrialNet. 19 A liquid meal is not truly physiologic however, and is associated with more rapid delivery of nutrients to the duodenum than after a solid meal. 33 It does however avoid the confounding of delayed gastric emptying which might be anticipated in a cohort with long diabetes duration and high prevalence of diabetic neuropathy.
Raised fasting and post-prandial glucose are secondary to defects in either insulin secretion, insulin sensitivity, or both. 34 The abnormal insulinogenic index and DI is consistent with defects in insulin secretion in these subjects with OGTT 120 ≥11.1 mmol/L post-islet transplantation. Loss of the first phase insulin response with diminished suppression of hepatic glucose production, may be associated with fasting glucose concentrations as low as 5.0-5.4 mmol/L, 35 and are well described in islet transplant recipients 10,36 concordant with our observations where a high prevalence of impaired fasting glucose was seen. The mechanism is not known but diminished pulsatility of insulin secretion may play a role. [37] [38] [39] [40] [41] [42] Such studies underline the importance of studying islet transplant participants distinct from other groups with diabetes and extrapolations of data from other subjects with diabetes including those who are C-peptide positive, may be inappropriate. 43, 44 Of note the subjects selected for islet transplantation were insulin sensitive with normal body mass index (BMI). 6 As insulin sensitivity was not measured by gold standard hyperinusulinaemic euglycaemic clamp studies, subtle defects in insulin sensitivity may have been missed. Certainly, immunosuppression with tacrolimus is recognized to induce insulin resistance and may contribute to insulin secretory deficits in some subjects; how this relates to the dose of immunosuppression as well as to their concentration is incompletely understood. [45] [46] [47] In this study, subjects were receiving sirolimus and The MMTT has been shown to be associated with lower glucose variability, fewer adverse symptoms and greater palatability vs the OGTT. 49 The primary analyses revealed a close relationship between the MMTT 90-minute glucose ≥8.0 mmol/L and glucose intolerance indicated by OGTT 120 ≥11.1 mmol/L. As the objective of metabolic testing is to assess graft function post hoc analyses were also performed to explore insulin secretion using ROC curves constructed using the DI < 1, a composite score reflecting defective insulin secretion in relation to the insulin sensitivity. 
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